Construction partner invests in Japan's UMN
This article was originally published in Scrip
IHI Plant Engineering Corp (IPEC) has signed an agreement to assist the Japanese bioventure UMN Pharma to construct a ¥2 billion domestic production facility for a novel vaccine against the H5N1 strain of bird flu. As part of the tie-up, IPEC, an affiliate of Japan's Ishikawajima-Harima Heavy Industries group, is to acquire a roughly 2% stake in UMN for around ¥200 million ($1.8 million). The recombinant vaccine, UMN-0501, uses protein expression technology licensed from Protein Sciences and recently entered clinical trials in Japan, where it has orphan status (Scrip Online, June 11th, 2008). The planned manufacturing facility will have an initial annual capacity of 10 million doses.
You may also be interested in...
Asia Deal Watch: RAPT And Hanmi Partner On CCR4 Antagonist Offering Potential In Multiple Cancer Types
RAPT can earn up to $108m in milestones plus sales royalties under the deal. BerGenBio, Piramal partner on developing AML therapy.
Japanese company starts pivotal trial with novel molecule as it looks to build oncology presence.
Gene And Cell Therapies In Asia: Pricing, Manufacturing Stand-Out Issues in Supportive Japan Ecosystem
The Japanese environment for cell and gene therapies and regenerative medicine in general continues to be highly supportive. But will pricing pressures under the NHI scheme move to the fore as more expensive products come to market?